AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions of claims in the application.

LISTING OF CLAIMS:

1. (currently amended) A non-effervescent tablet for oral administration of sodium naproxen comprising a tablet core and, ~~if desired~~ optionally, a sugar or film coat on the tablet core, wherein the tablet core consists of 30 to 95%[[99%]] by weight of sodium naproxen and 70 to 5% [[1%]] by weight of auxiliary agent component comprising at least one or more basic auxiliary agent, the total quantity of said auxiliary agent in said component being at least 5% by weight based on the weight of the tablet core.

2. (cancelled).

3. (currently amended) The tablet as claimed in claim 1 [[2]], wherein the tablet core consists of 60 to 95% by weight of sodium naproxen and 40 to 5% by weight of auxiliary agent component, based on the weight of the tablet core.

4. (previously presented) The tablet as claimed in claim 3, wherein the tablet core consists of 70 to 93% by weight of sodium naproxen and 30 to 7% by weight of auxiliary agent component, based on the weight of the tablet core.

5. (previously presented) The tablet as claimed in claim 4, wherein the sodium naproxen has a water content of 0.05 to 14% by weight.

6. (previously presented) The tablet as claimed in claim 5, wherein the sodium naproxen has a water content of 6 to 12.5% by weight.

7. (cancelled).

8. (currently amended) The tablet as claimed in claim 1 [[7]], wherein the auxiliary agent component comprises one or more basic auxiliary agents in a total

quantity of 10 to 30% by weight, based on the weight of the tablet core.

9. (currently amended) The tablet as claimed in claim 1 [[7]], wherein the auxiliary agent component comprises one or more basic auxiliary agents in a total quantity of said auxiliary agent in said component being from 15 to 25% by weight, based on the weight of the tablet core.

10. (previously presented) The tablet as claimed in claim 1, wherein the basic auxiliary agent is water soluble.

11. (currently amended) The tablet as claimed in claim 1, wherein the basic auxiliary agent is selected from the group consisting of basic alkali metal salts, basic alkaline earth metal salts, basic ammonium salts and basic amino acids.

12. (currently amended) The tablet as claimed in claim 11, wherein the basic auxiliary agent is selected from the group consisting of sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, trisodium citrate and trisodium phosphate.

13. (currently amended) The tablet as claimed in claim 12, wherein the basic auxiliary agent is selected from the group consisting of sodium hydrogen carbonate and potassium hydrogen carbonate.

14. (previously presented) The tablet as claimed in claim 1, wherein the auxiliary agent component comprises one or more neutral to weakly acidic fillers that improve the compressibility.

15. (previously presented) The tablet as claimed in claim 1, wherein the auxiliary agent component comprises one or more water soluble, neutral to weakly acidic fillers that improve the compressibility.

16. (currently amended) The tablet as claimed in claim 15, wherein the auxiliary agent component comprises one or more fillers, selected from the group consisting of sugars, hexoses, hydrolysed or enzymatically split starches, cyclodextrins, non-

crosslinked polyvinylpyrrolidone, neutral to weakly acidic alkali metal salts, neutral to weakly acidic alkaline earth metal salts, and neutral to weakly acidic ammonium salts.

17. (currently amended) The tablet as claimed in claim 16, wherein the auxiliary agent component comprises one or more fillers, selected from the group consisting of hexoses, non-crosslinked polyvinylpyrrolidone, maltodextrin and sodium chloride.

18. (previously presented) The tablet as claimed in claim 17, wherein the auxiliary agent component comprises non-crosslinked polyvinylpyrrolidone as filler.

19. (previously presented) The tablet as claimed in claim 14, wherein the auxiliary agent component comprises one or more non-water soluble fillers that improve the compressibility and the tablet disintegration.

20. (currently amended) The tablet as claimed in claim 19, wherein the auxiliary agent component comprises one or more fillers, selected from the group consisting of native and microcrystalline celluloses, starches, modified starches, calcium phosphates and silicon oxide.

21. (previously presented) The tablet as claimed in claim 14, wherein the proportion of filler is 1 to 50% by weight, based on the weight of the tablet core.

22. (previously presented) The tablet as claimed in claim 21, wherein the proportion of filler is 3 to 30% by weight, based on the weight of the tablet core.

23. (previously presented) The tablet as claimed in claim 22, wherein the proportion of filler is 10 to 25% by weight, based on the weight of the tablet core.

24. (currently amended) The tablet as claimed in claim 1, wherein the auxiliary agent component comprises at least one basic auxiliary agent, selected from the group consisting of sodium hydrogen carbonate and potassium hydrogen carbonate, and non-crosslinked polyvinylpyrrolidone as filler.

25. (currently amended) The tablet as claimed in claim 24, wherein the auxiliary agent component comprises, based on the weight of the tablet core, 5 to 20% by weight of basic auxiliary agent, selected from the group consisting of sodium hydrogen carbonate and potassium hydrogen carbonate, and 5 to 20% by weight of non-crosslinked polyvinylpyrrolidone as filler.

26. (previously presented) A tablet as claimed in claim 1, wherein the auxiliary agent component comprises a disintegrant.

27. (currently amended) A tablet as claimed in claim 26, wherein the auxiliary agent component comprises a disintegrant selected from the group consisting of croscarmellose, crospovidone and crosslinked sodium carboxymethyl starch.

28. (previously presented) A tablet as claimed in claim 1, wherein the auxiliary agent component comprises one or more lubricants and/or glidants.

29. (previously presented) A tablet as claimed in claim 1, wherein the tablet core does not contain any lubricant and does not contain any glidant.

30. (previously presented) A tablet as claimed in claim 1, wherein the auxiliary agent component contains one or more ionic or non-ionic tensides.

31. (currently amended) A tablet as claimed in claim 30, wherein the auxiliary agent component contains one or more tensides, selected from the group consisting of sodium lauryl sulphate, sodium dodecyl sulphate, polysorbate and saccharose monopalmitate.

32. (previously presented) A tablet as claimed in claim 30, wherein the proportion of tenside is 0.1 to 5% by weight, based on the weight of the tablet core.

33. (previously presented) A tablet as claimed in claim 1, wherein the tablet core consists of a granulate with a granular size distribution from 0.25 to 1.25 mm.

34. (previously presented) A tablet as claimed in claim 1, wherein the hardness of

the tablet core is at least 30 N.

35. (previously presented) A tablet as claimed in claim 1 with a content of sodium naproxen of 110 to 660 mg, based on the water-free sodium naproxen.

36. (previously presented) A tablet as claimed in claim 1, wherein the tablet core consists of sodium naproxen and basic auxiliary agent.

37. (previously presented) A tablet as claimed in claim 1, comprising sodium naproxen, sodium hydrogen carbonate, microcrystalline cellulose, croscarmellose, talc, and magnesium stearate.

38. (previously presented) A tablet as claimed in claim 37, comprising 50 to 60 % by weight of sodium naproxen, 15 to 25 % by weight of sodium hydrogen carbonate, 15 to 25 % by weight of microcrystalline cellulose, 2 to 6 % by weight of croscarmellose, 1 to 5 % by weight of talc, and 0.5 to 2.2 % by weight of magnesium stearate.

39. (previously presented) A tablet as claimed in claim 37, comprising 55 to 65 % by weight of sodium naproxen, 10 to 25 % by weight of sodium hydrogen carbonate, 2 to 15 % by weight of microcrystalline cellulose, 2 to 6 % by weight of croscarmellose, 1 to 5 % by weight of talc, and 0.5 to 2.2 % by weight of magnesium stearate.

40. (previously presented) A tablet as claimed in claim 39, comprising 55 to 65 % by weight of sodium naproxen, 10 to 25 % by weight of sodium hydrogen carbonate, 5 to 10 % by weight of hydroxyl propyl cellulose, 2 to 15 % by weight of microcrystalline cellulose, 2 to 6 % by weight of croscarmellose, 1 to 5 % by weight of talc, and 0.5 to 2.2 % by weight of magnesium stearate.

41. (currently amended) A process for producing a non-effervescent tablet for oral administration of sodium naproxen comprising a tablet core and, ~~if desired~~ optionally, a sugar or film coat on the tablet core, wherein the tablet core consists of 30 to 95% [[99%]] by weight sodium naproxen and 70 to 5% [[1%]] by weight auxiliary agent component, comprising ~~at least~~ one or more basic auxiliary agent,

based on the weight of the tablet core, characterized in that a mixture of the sodium naproxen and the auxiliary agent component is compressed into the tablet cores and, ~~if desired~~ optionally, the tablet cores ~~are~~ can be coated with a sugar or film coat.